Developing a new treatment for tuberculosis targeting a specific enzyme
A Preclinical Program for Targeting Mycobacterium tuberculosis KasA
This study is testing a new drug called JSF-3285 to see how well it can help treat tuberculosis, and it's aimed at making it available for people with this infection in the next few years.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10901964 on NIH RePORTER |
What this research studies
This research focuses on the development of a new drug candidate, JSF-3285, which targets the essential enzyme KasA in Mycobacterium tuberculosis. The project involves optimizing this compound based on previous findings and conducting studies to assess its effectiveness in treating both acute and chronic tuberculosis infections in animal models. Researchers will also explore drug combinations and conduct relapse studies to prepare for clinical trials. The goal is to advance this candidate towards clinical use within the next five years.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from tuberculosis, particularly those with drug-resistant strains.
Not a fit: Patients with non-tuberculosis related infections or conditions will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for drug-resistant tuberculosis.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in tuberculosis, indicating potential for success with this approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Freundlich, Joel Stephen — Rutgers Biomedical and Health Sciences
- Study coordinator: Freundlich, Joel Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.